Hitz Launches 'AI Scientist Partner Program' with KAIST AI-CRED Research Group

Refining the Platform with Feedback from Research Labs
Improving the “Homegrown AI Scientist” Product Ahead of Its November 26 Launch

Hitz, an artificial intelligence (AI) bio platform company, announced on November 9 that it had signed a memorandum of understanding (MOU) with the KAIST AI-CRED Research Group to run the HyperLab AI Scientist Partner Program.

AI-CRED is a KAIST-led national strategic convergence research group that integrates AI technology across the entire drug development process. It conducts research spanning the full scope of drug development, including AI-based protein design, omics analysis, structural design of candidate compounds, drug delivery system (DDS) development, preclinical research, and efficacy evaluation.

Lee Heeseung, head of the KAIST AI-CRED Research Group (left), and HITS CEO Kim Wooyeon pose for a commemorative photo at the MOU signing ceremony for the “HyperLab AI Scientist Partner Program.” HITS

Under the agreement, up to 50 selected doctoral and postdoctoral researchers from AI-CRED will use Hitz's agentic AI-based research platform, HyperLab, directly in their own research projects as “research partners” for five months, from November 2026 through March 2027. Rather than working on prescribed test assignments, participating researchers will apply the platform to their own research and directly assess AI's potential and limitations. Through surveys and interviews, Hitz plans to gather feedback on efficiency compared with existing research methods, the accuracy and reliability of results, and areas for improvement in practical research settings, and actively incorporate it into HyperLab's further development.

Hitz recently introduced large language models (LLMs) to HyperLab and is developing the service into an “AI colleague scientist” that designs and conducts research alongside researchers. Through this program, the company plans to continue incorporating user experience and feedback gathered from drug development research settings into the further development of its homegrown AI Scientist product, which is scheduled for official release on November 26.

“Hitz plans to continually advance the bio-specialization of foundation models based on real-world experiences and feedback voluntarily provided by our core users,” said Hitz CEO Kim Wooyeon. “With our AI technology and engineering capabilities, we will establish a global standard for AI in bio research and develop Hitz's AI Scientist solution into a trusted partner for biopharmaceutical research and development, differentiated from global big tech companies.”

This content was produced with the assistance of AI translation services.